1213269-23-8 | N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
5mg	98%	in stock	$18.00	$12.00
10mg	98%	in stock	$22.00	$15.00
50mg	98%	in stock	$26.00	$18.00
100mg	98%	in stock	$44.00	$31.00
250mg	98%	in stock	$50.00	$35.00
1g	98%	in stock	$110.00	$77.00
5g	98%	in stock	$337.00	$236.00

Description

• Catalog Number: AD74703
• Chemical Name: N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide
• CAS Number: 1213269-23-8
• Molecular Formula: C25H27ClN6O3
• Molecular Weight: 494.9733
• MDL Number: MFCD16621244
• SMILES: C=CC(=O)Nc1cccc(c1)Oc1nc(ncc1Cl)Nc1ccc(cc1OC)N1CCN(CC1)C

Computed Properties

• Complexity: 694
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: 4.2

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

  Molecular cancer therapeutics 20121001

• Irreversible protein kinase inhibitors: balancing the benefits and risks.

  Journal of medicinal chemistry 20120726

• NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.

  Biochemical and biophysical research communications 20120713

• Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

• Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.

  Journal of medicinal chemistry 20120322

• WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.

  Laboratory investigation; a journal of technical methods and pathology 20120301

• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

  Nature 20091224